替诺福韦艾拉酚胺作为一例有范可尼综合征和多药耐药史的HBV肝硬化患者的挽救治疗
本文报道一例75岁女性HBV单纯感染合并代偿性肝硬化患者,在长期拉米夫定和阿德福韦治疗及替诺福韦酯诱导的范可尼综合征后出现恩替卡韦耐药株和3级慢性肾病。给予同情用药计划下的替诺福韦艾拉酚胺25mg/天,快速抑制病毒复制至检测不到水平,且未加重肾功能或出现副作用。
要点
- 替诺福韦酯是慢性乙型肝炎一线推荐治疗,但部分患者可出现肾小球滤过率下降、低磷血症、高磷尿症和范可尼综合征。
- 有拉米夫定治疗史的患者使用恩替卡韦可发生耐药株,可能导致潜在严重的肝炎 flare。
- 替诺福韦艾拉酚胺25mg/天在此例中快速抑制病毒至检测不到水平,未加重肾功能或出现副作用。
核心结论
- 替诺福韦艾拉酚胺25mg/天在此例有范可尼综合征和多药耐药史的HBV肝硬化患者中快速抑制病毒复制至检测不到水平,未加重肾功能或出现副作用。
研究设计与样本
- 本文为一例病例报告,描述一名75岁女性HBV单纯感染合并代偿性肝硬化患者。
主要发现
- 患者在接受多年拉米夫定和阿德福韦治疗及替诺福韦酯诱导的范可尼综合征后,出现恩替卡韦耐药株和3级慢性肾病。
- 给予同情用药计划下的替诺福韦艾拉酚胺25mg/天,病毒复制快速抑制至检测不到水平,未加重肾功能或出现副作用。
关键数值与推荐
- 替诺福韦艾拉酚胺剂量为25mg/天,通过同情用药计划给予。
临床怎么用
- 作者描述在此例患者中使用替诺福韦艾拉酚胺25mg/天作为挽救治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tenofovir disoproxil fumarate (TDF) is a recommended first-line therapy for both naïve and experienced patients with chronic hepatitis B (CHB), although reduced estimated glomerular filtration rate (eGFR), hypophosphatemia, hyperphosphaturia and Fanconi syndrome have been reported in some patients. Entecavir (ETV) could be considered as a rescue therapy for TDF-treated patients developing renal dysfunction, though patients with prior history of treatment with lamivudine (LAM) can develop ETV resistance strains, which can lead to potentially severe hepatitis flares. Tenofovir alafenamide (TAF), a new prodrug of tenofovir, has recently been developed to improve the renal and bone safety profile compared to TDF, while maintaining the same virologic efficacy. The recently published 48-week phase III TAF registration studies confirmed the superior safety profile. Here we describe a case of a 75-year-old woman with HBV mono-infection and compensated cirrhosis who developed ETV resistant strains and grade 3 chronic kidney disease after many years of LAM and adefovir (ADV) treatment and a TDF-induced Fanconi syndrome. The administration of 25mg/day of TAF, granted as part of a compassionate use program, rapidly suppressed viral replication to undetectable levels without worsening renal function or side effects.
引用
- Grossi G, Loglio A, Facchetti F, et al. Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. J Hepatol. 2017. PMID: 28870666. doi:10.1016/j.jhep.2017.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。